ReviewAdvances in experimental medicine and biology
A Novel Strategy for Simple and Robust Expansion of Human Pluripotent Stem Cells Using Botulinum Hemagglutinin.
Review in Advances in experimental medicine and biology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
- Cross-linking methods of type I collagen-based scaffolds for cartilage tissue engineering.American journal of translational research · 2022Review
- Process parameter development for the scaled generation of stem cell-derived pancreatic endocrine cells.Stem cells translational medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clinical and industrial application of human pluripotent stem cells (hPSCs) has been hindered by the lack of robust strategies to sustain cultures in an undifferentiated state. Here, we describe a simple and robust method to culture and propagate hPSCs, which we anticipate will remove major roadblocks in investigating the basic properties of undifferentiated hPSCs and accelerate cell-based manufacturing. We also provide an overview of the use of botulinum hemagglutinin, an inhibitor of E-cadherin, to maintain and expand various hPSC lines in an undifferentiated state in different culture conditions. Hemagglutinin selectively removes cells that have lost the undifferentiated state, dissociates aggregates in situ, and is easy to use, scalable, and reproducible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.